Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Daunorubicin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TOP2A known ✓ | P11388 | 5/20 | 0.85 |
| ▸ | MEN1 | O00255 | 10/20 | 0.85 |
| ▸ | THRB | P10828 | 10/20 | 0.85 |
| ▸ | KMT2A | Q03164 | 10/20 | 0.85 |
| ▸ | BLM | P54132 | 9/20 | 0.85 |
| ▸ | RECQL | P46063 | 8/20 | 0.85 |
| ▸ | BRCA1 | P38398 | 7/20 | 0.85 |
| ▸ | SMN1; SMN2 | Q16637 | 7/20 | 0.85 |
| ▸ | HIF1A | Q16665 | 7/20 | 0.85 |
| ▸ | MAPT | P10636 | 7/20 | 0.85 |
| ▸ | TDP1 | Q9NUW8 | 6/20 | 0.85 |
| ▸ | MAPK1 | P28482 | 6/20 | 0.85 |
| ▸ | CYP3A4 | P08684 | 5/20 | 0.85 |
| ▸ | USP2 | O75604 | 5/20 | 0.85 |
| ▸ | HTT | P42858 | 5/20 | 0.85 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.85 |
| ▸ | CHRM1 | P11229 | 4/20 | 0.85 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.85 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.85 |
| ▸ | TBXA2R | P21731 | 3/20 | 0.85 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Daunorubicin SCHEMBL29354629 | 1.00 | MEN1 (0.85) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL22534202 | 0.99 | MEN1 (0.85) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL3644783 | 0.99 | MEN1 (0.85) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL23909361 | 0.98 | MEN1 (0.82) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL23909359 | 0.98 | MEN1 (0.82) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL19024333 | 0.96 | MEN1 (0.83) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL1071625 | 0.94 | MEN1 (0.87) | MEN1THRBKMT2ABLMRECQL | |
| Epirubicin SCHEMBL23909357 | 0.94 | MEN1 (0.87) | MEN1THRBKMT2ABLMRECQL | |
| Doxorubicin SCHEMBL14953344 | 0.93 | MEN1 (0.87) | MEN1THRBKMT2ABLMRECQL | |
| Daunorubicin SCHEMBL24914323 | 0.92 | MEN1 (1.00) | MEN1THRBKMT2ABLMRECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 3299 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4694915-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| EP-4694914-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE LTD (SG) | 2026-02-18 | — | — | EP | claimed |
| US-12527836-B2 | Gla domains as targeting agents | GLAdiator Biosciences, Inc. (US) | 2026-01-20 | — | — | US | claimed |
| US-12325755-B2 | Macropinocytosing human anti-CD46 antibodies and targeted cancer therapeutics | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-06-10 | — | — | US | claimed |
| WO-2024213648-A1 | TREATMENT OF HAEMATOLOGICAL CANCER | STERLING IP PTE. LTD. (SG) | 2024-10-17 | — | — | WO | claimed |
| WO-2024213640-A1 | INHIBITION OF: STROMA/CANCER CELL CROSS-TALK &/OR STROMA GENERATED RESISTANCE TO TREATMENT | STERLING IP PTE. LTD. (SG) | 2024-10-17 | — | — | WO | claimed |
| WO-2024105553-A1 | BICYCLIC HETEROCYCLES AND THEIR USE AS WRN INHIBITORS | NOVARTIS AG (CH) | 2024-05-23 | — | — | WO | claimed |
| WO-2024079623-A1 | TRICYCLIC COMPOUNDS AND THEIR USES | NOVARTIS AG (CH) | 2024-04-18 | — | — | WO | claimed |
| EP-4347596-A1 | TRIAZOLO-PYRIMIDINE ANALOGUES FOR TREATING DISEASES CONNECTED TO THE INHIBITON OF WERNER SYNDROME RECQ HELICASE (WRN) | Novartis AG (CH) | 2024-04-10 | — | — | EP | claimed |
| EP-3383920-B1 | TUMOR-SPECIFIC PAYLOAD DELIVERY AND IMMUNE ACTIVATION USING A HUMAN ANTIBODY TARGETING A HIGHLY SPECIFIC TUMOR CELL SURFACE ANTIGEN | UNIV CALIFORNIA (US) | 2024-01-10 | — | — | EP | claimed |
| WO-2011009059-A2 | METHOD OF TREATING OR PREVENTING CANCER | THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 2011-01-20 | — | — | WO | claimed |
| WO-2008116165-A9 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY INC (US) | 2009-06-11 | — | — | WO | claimed |
| WO-2008116165-A2 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | NEXT SAFETY, INC. (US) | 2008-09-25 | — | — | WO | claimed |
| US-20080066741-A1 | METHODS AND SYSTEMS OF DELIVERING MEDICATION VIA INHALATION | HUNTER, CHARLES ERIC | 2008-03-20 | — | — | US | claimed |
| US-20070292396-A1 | COMBINATION THERAPY WITH ONCOLYTIC ADENOVIRUS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM | 2007-12-20 | — | — | US | claimed |
| WO-2007103825-A2 | COMBINATION THERAPY WITH ONCOLYTIC ADENOVIRUS | THE BOARD OF REGENTS OF THE UNIVERSITY OF TEXAS SYSTEM (US) | 2007-09-13 | — | — | WO | claimed |
| EP-1357935-B1 | REDUCING SIDE EFFECTS OF CHEMOTHERAPY IN CANCER PATIENTS | SCICLONE PHARMACEUTICALS INC (US) | 2006-12-20 | — | — | EP | claimed |
| US-6589941-B1 | Preventing or reducing formation of resistance in cytostatic treatment comprising combining BVDU, a salt thereof or BVDU in protected form or in prodrug form with at least one cytostatic agent in order to prevent or reduce the formation | RESPROTECT GMBH (DE) | 2003-07-08 | — | — | US | claimed |
| US-6581606-B2 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response | THE RX FILES CORPORATION | 2003-06-24 | — | — | US | claimed |
| US-20010018919-A1 | Method, apparatus and system for use in treating patient with a drug having an antineoplastic effect to optimize therapy and prevent an adverse drug response | DIMENSIONAL DOSING SYSTEMS, INCORPORATED | 2001-09-06 | — | — | US | claimed |